FIELD: biochemistry.
SUBSTANCE: invention relates to an antibody which binds to an activating factor protein of pancreatic adenocarcinoma (PAUF). Also disclosed is a polynucleotide encoding said antibody; an expression vector and a transformant containing said polynucleotide; pharmaceutical composition, conjugate, kit containing said antibody. What is disclosed are methods for preventing or treating cancer, inhibiting proliferation, migration or invasion of cancer cells, diagnosing cancer and screening with said antibody.
EFFECT: invention is capable to effectively treat cancer diseases, where cancer is pancreatic cancer or ovarian cancer.
14 cl, 16 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ANTIBODIES AGAINST VISTA AND APPLICATION THEREOF | 2018 |
|
RU2750723C1 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| ANTIBODY AGAINST ANG2 AND ITS USE | 2020 |
|
RU2788088C1 |
| ANTI-DR5 ANTIBODY AND USE THEREOF | 2018 |
|
RU2735956C1 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804772C2 |
| THIOREDOXIN-1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO IT | 2018 |
|
RU2797266C2 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804126C2 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2023 |
|
RU2802944C1 |
| MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO THE THIOREDOXIN-1 EPITOPE, ITS PREPARATION AND APPLICATION | 2018 |
|
RU2791264C2 |
